Clinical trial NCT03206905: Safety, Tolerability, and Sustained Weight Loss of Endoscopic Sleeve Gastroplasty With Diet Modification and Exercise
Official title: Safety, Tolerability and Sustained Weight Loss of Immediate Endoscopic Sleeve Gastroplasty (ESG) With Diet Modification and Exercise vs. Early Diet Modification and Exercise and Delayed ESG for the Treatment of Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2017-07-02
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the effect of endoscopic sleeve gastroplasty (ESG) with diet and exercise, to diet and exercise alone, to see which is better in weight loss reduction. Investigators will also compare the effects of ESG to diet and exercise comorbidities such as diabetes, sleep apnea and high cholesterol as well as the various obesity related hormones.

Detailed description: This is a single center, prospective randomized case control study with an additional non randomized case arm. This study includes two research interventional groups. Groups A: ESG with diet and exercise modules. Group B: Diet and exercise modules only. Investigators propose to compare ESG to behavioral modification including diet and exercise for patients who have a BMI greater than or equal to 40 kg/m2 or greater than or equal to 30 kg/m2 with 1 or more obesity related co-morbidity and who cannot undergo conventional bariatric surgery(or decline the surgical option). Investigators will also compare the effects of ESG to diet and exercise on comorbidities such as diabetes, sleep apnea and high cholesterol as well as the various obesity related hormones.

Eligibility criteria: Inclusion Criteria:

* BMI greater than or equal to 40 kg/m2, greater than or equal to to 30 kg/m2 with 1 more obesity related co-morbidity, or or greater than or equal to 35 kg/m2 without co-morbidity

Co-morbidities include:

1. Sleep apnea (STOP-BANG questionnaire and polysomnography)
2. BP \>130/80 or on hypertension meds.
3. A1c \> or = to 5.7, fasting \>100 OR RANDOM \>126, exclude 6.5 and above
4. Waist circumference \>102, or 40 inches if male or \>80 cm 35 inches if female
5. Metabolic syndrome (3 criteria, blood pressure, waist circumference, triglycerides \> 150 or HDL \< 50/40)

   * Failure to respond to non-invasive weight loss management for at least 6 months.
   * Valid health insurance to cover the cost of procedure and standard of care pre-and post-procedure management/workup.

Exclusion Criteria:

* Untreated endocrine diseases (diabetes, thyroid disorder, pituitary disorder, and sex gland disorder).
* diabetes or A1c \>6.5
* Heart Disease, for example, arrhythmia, heart failure, myocardial infarction.
* Kidney disease with serum creatinine greater than 2.5 mg/dl.
* Cerebrovascular disease, for example, stroke or otherwise unable to exercise.
* Any pregnant or lactating women or who have had childbirth within 6 months.
* Any patients on retinoid therapy or undergoing retinoid therapy that will not last throughout the length of the trial.
* Patients with significant psychiatric disorder.
* Any other chronic condition deemed unsuitable to undergo either arm of the trial.

Primary outcomes:
measure: Mean Percentage of Total Body Weight Loss
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medicine, Division of Gastroenterology & Hepatology
state: New York
Study officials:
affiliation: Assistant Professor of Medicine
name: Reem Sharaiha, MD
role: PRINCIPAL_INVESTIGATOR
References: